Hurvitz Chaim
Known title: DirectorCIK: 0001630542
Hurvitz Chaim's purchase track record
Hurvitz Chaim has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/30/2023 | NRXP | $20K | +7.3% | -3.8% | +12.3% |
| 11/16/2022 | NRXP | $515K | +1.9% | -35.2% | +5.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NRXP | ▲ Buy | Open Market | 70,000 | $20K | 8/30/2023 | View on chart |
| NRXP | ▲ Buy | Open Market | 40,408 | $44K | 11/18/2022 | View on chart |
| NRXP | ▲ Buy | Open Market | 171,780 | $186K | 11/17/2022 | View on chart |
| NRXP | ▲ Buy | Open Market | 287,812 | $285K | 11/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership
Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership. Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.